scholarly journals Brigatinib (BRG) in Crizotinib (CRZ)-Refractory ALK+ Non–Small Cell Lung Cancer (NSCLC): efficacy and safety results from ALTA, a pivotal randomized phase 2 Trial

2016 ◽  
Vol 27 ◽  
pp. iv4
Author(s):  
D. Kim ◽  
M. Tiseo ◽  
M. Ahn ◽  
K. Reckamp ◽  
K. Holmskov Hansen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Efficacy And Safety ◽  
Small Cell Lung ◽  
Phase 2 Trial ◽  
Randomized Phase 2

scholarly journals Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer

Cancer ◽  
2015 ◽  
Vol 121 (18) ◽  
pp. 3298-3306 ◽  
Author(s):  
Karen L. Reckamp ◽  
Marianna Koczywas ◽  
Mihaela C. Cristea ◽  
Jonathan E. Dowell ◽  
He-Jing Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
High Dose ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Phase 2 Trial ◽  
Randomized Phase 2
Sign in / Sign up

Export Citation Format

Share Document